New, shorter drug-resistant tuberculosis treatment shows promise
Paris, Nov 20 (IANS) New, shorter drug-resistant tuberculosis (TB) treatment -- BPaL (comprised of bedaquiline, pretomanid, and linezolid) -- showed a 94.5 per cent cure rate in countries with a high burden of drug-resistant TB (DR-TB), reveals interim research results from five Central and Southeast Asian countries.